Desidustat

Cat. No.:	HY-103227		
CAS No.:	1616690-16	-4	
Molecular Formula:	$C_{16}H_{16}N_{2}O_{6}$		
Molecular Weight:	332.31		
Target:	HIF/HIF Pro	lyl-Hydro	oxylase
Pathway:	Metabolic E	inzyme/P	rotease
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year

®

MedChemExpress

SOLVENT & SOLUBILITY

In Vitro	DMSO : 10 mg/mL (30.09 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	3.0092 mL	15.0462 mL	30.0924 mL	
		5 mM	0.6018 mL	3.0092 mL	6.0185 mL	
		10 mM	0.3009 mL	1.5046 mL	3.0092 mL	
	Please refer to the solubility information to select the appropriate solvent.					
In Vivo	 Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1 mg/mL (3.01 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1 mg/mL (3.01 mM); Clear solution 					

BIOLOGICAL ACTIV	ΥITY			
Description	Desidustat is an orally active HIF hydroxylase inhibitor. Desidustat can be used for the research of various disorders including anemia of different types and conditions associated with ischemia/hypoxia ^[1] .			
In Vivo	Desidustat (oral; 10-10 MCE has not independ	00 mg/kg) has good efficacy in vivo ^[1] . lently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	C57 Mice ^[1]		
	Dosage:	10, 30, 50, 100 mg/kg;		

Q

0

OH O

OH

	20 mg /kg
Administration:	oral gavage; oral, once, daily, for 7 days
Result:	Significant increased the level of EPO and Hb.

CUSTOMER VALIDATION

- Drug Test Anal. 2020 Aug 27.
- J Anal Toxicol. 2020 May 20;bkaa055.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Ranjit C, et al. Novel quinolone derivatives. Patent. WO2014102818A1.

Caution: Product has not been fully validated for medical applications. For research use only.